Genetic factors associated with prostate cancer conversion from active surveillance to treatment

Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for PC, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and ge...

Full description

Saved in:

Bibliographic Details
Published in:	HGG advances Vol. 3; no. 1; p. 100070
Main Authors:	Jiang, Yu, Meyers, Travis J., Emeka, Adaeze A., Cooley, Lauren Folgosa, Cooper, Phillip R., Lancki, Nicola, Helenowski, Irene, Kachuri, Linda, Lin, Daniel W., Stanford, Janet L., Newcomb, Lisa F., Kolb, Suzanne, Finelli, Antonio, Fleshner, Neil E., Komisarenko, Maria, Eastham, James A., Ehdaie, Behfar, Benfante, Nicole, Logothetis, Christopher J., Gregg, Justin R., Perez, Cherie A., Garza, Sergio, Kim, Jeri, Marks, Leonard S., Delfin, Merdie, Barsa, Danielle, Vesprini, Danny, Klotz, Laurence H., Loblaw, Andrew, Mamedov, Alexandre, Goldenberg, S. Larry, Higano, Celestia S., Spillane, Maria, Wu, Eugenia, Carter, H. Ballentine, Pavlovich, Christian P., Mamawala, Mufaddal, Landis, Tricia, Carroll, Peter R., Chan, June M., Cooperberg, Matthew R., Cowan, Janet E., Morgan, Todd M., Siddiqui, Javed, Martin, Rabia, Klein, Eric A., Brittain, Karen, Gotwald, Paige, Barocas, Daniel A., Dallmer, Jeremiah R., Gordetsky, Jennifer B., Steele, Pam, Kundu, Shilajit D., Stockdale, Jazmine, Roobol, Monique J., Venderbos, Lionne D.F., Sanda, Martin G., Arnold, Rebecca, Patil, Dattatraya, Evans, Christopher P., Dall’Era, Marc A., Vij, Anjali, Costello, Anthony J., Chow, Ken, Corcoran, Niall M., Rais-Bahrami, Soroush, Phares, Courtney, Scherr, Douglas S., Flynn, Thomas, Karnes, R. Jeffrey, Koch, Michael, Dhondt, Courtney Rose, Nelson, Joel B., McBride, Dawn, Cookson, Michael S., Stratton, Kelly L., Farriester, Stephen, Hemken, Erin, Stadler, Walter M., Pera, Tuula, Banionyte, Deimante, Bianco, Fernando J., Lopez, Isabel H., Loeb, Stacy, Taneja, Samir S., Byrne, Nataliya, Amling, Christopher L., Martinez, Ann, Boileau, Luc, Gaylis, Franklin D., Petkewicz, Jacqueline, Kirwen, Nicholas, Helfand, Brian T., Xu, Jianfeng, Scholtens, Denise M., Catalona, William J., Witte, John S.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 13-01-2022 Elsevier
Subjects:	genetics genome-wide association study prostate prostatic neoplasms prostate genetics prostatic neoplasms genome-wide association study
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for PC, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of which were not previously associated with PC risk. With a transcriptome-wide association study (TWAS), we found two genes associated with conversion (MAST3, p = 6.9 × 10−7 and GAB2, p = 2.0 × 10−6). Moreover, increasing values of a previously validated 269-variant genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% confidence interval [CI] = 0.94–1.36); whereas decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04–1.50). These results suggest that germline genetics may help inform and individualize the decision of AS—or the intensity of monitoring on AS—versus treatment for the initial management of patients with low-risk PC. Genetic factors may distinguish who should receive active surveillance (AS) versus treatment following prostate cancer diagnosis. We undertook the first study to investigate this and report novel variants, genes, and risk scores associated with AS outcomes. These findings could help inform and individualize the decision of AS.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally
ISSN:	2666-2477 2666-2477
DOI:	10.1016/j.xhgg.2021.100070